CA2777782C - Sepiapterin reductase inhibitors for the treatment of pain - Google Patents

Sepiapterin reductase inhibitors for the treatment of pain Download PDF

Info

Publication number
CA2777782C
CA2777782C CA2777782A CA2777782A CA2777782C CA 2777782 C CA2777782 C CA 2777782C CA 2777782 A CA2777782 A CA 2777782A CA 2777782 A CA2777782 A CA 2777782A CA 2777782 C CA2777782 C CA 2777782C
Authority
CA
Canada
Prior art keywords
mmol
compound
pain
reaction mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2777782A
Other languages
English (en)
French (fr)
Other versions
CA2777782A1 (en
Inventor
Julian Blagg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA2777782A1 publication Critical patent/CA2777782A1/en
Application granted granted Critical
Publication of CA2777782C publication Critical patent/CA2777782C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CA2777782A 2009-10-15 2010-10-14 Sepiapterin reductase inhibitors for the treatment of pain Expired - Fee Related CA2777782C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25201309P 2009-10-15 2009-10-15
US61/252,013 2009-10-15
PCT/US2010/052674 WO2011047156A1 (en) 2009-10-15 2010-10-14 Sepiapterin reductase inhibitors for the treatment of pain

Publications (2)

Publication Number Publication Date
CA2777782A1 CA2777782A1 (en) 2011-04-21
CA2777782C true CA2777782C (en) 2016-06-28

Family

ID=43876540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777782A Expired - Fee Related CA2777782C (en) 2009-10-15 2010-10-14 Sepiapterin reductase inhibitors for the treatment of pain

Country Status (6)

Country Link
US (2) US9169234B2 (OSRAM)
EP (1) EP2488025A4 (OSRAM)
JP (1) JP5758395B2 (OSRAM)
AU (1) AU2010306750B2 (OSRAM)
CA (1) CA2777782C (OSRAM)
WO (1) WO2011047156A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001327A (es) 2006-08-07 2009-06-05 Ironwood Pharmaceuticals Inc Compuestos de indol.
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN102329263A (zh) * 2011-10-17 2012-01-25 上海化学试剂研究所 一种n-乙酰基-5-甲氧基色胺的制备方法
JP6419783B2 (ja) 2013-04-15 2018-11-07 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 殺菌・殺カビ性アミド
BR112016010568B1 (pt) * 2013-11-15 2021-09-21 Bayer Cropscience Aktiengesellschaft Processo para preparação de um derivado de 2-etilaminopiridina substituída
EP3213062B1 (en) * 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
WO2017059191A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Heteroaryl derivatives as sepiapterin reductase inhibitors
JP6555702B2 (ja) * 2016-01-26 2019-08-07 アタトゥルク ユニヴァーシテシ ビリムセル アラスティルマ プロジェレリ ビリミ Ｎ３，ｎ５‐ビス（２‐（５‐メトキシ‐１ｈ‐インドール‐３‐イル）エチル）‐２，６‐ジメチル‐４‐（２‐ニトロフェニル）ピリジン‐３，５‐ジカルボキシアミドおよび神経毒分野におけるその使用
US20170291372A1 (en) * 2016-04-09 2017-10-12 Velo3D, Inc. Generating three-dimensional objects by three-dimensional printing with rotation
AU2017258304B2 (en) 2016-04-27 2019-07-04 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases
ES2912531T3 (es) 2016-12-21 2022-05-26 Bayer Cropscience Ag Hidrogenación de un derivado de 2-metil cianopiridilo sustituido en presencia de un catalizador de cobalto Raney
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
CN108689856A (zh) * 2018-07-09 2018-10-23 上海华堇生物技术有限责任公司 一种3-羟基-β-硝基苯乙烯的新制备方法
US11270771B2 (en) * 2019-01-29 2022-03-08 Silicon Storage Technology, Inc. Neural network classifier using array of stacked gate non-volatile memory cells
EP4219500A4 (en) 2020-04-14 2024-10-23 Nissan Chemical Corporation FUSED HETEROCYCLIC COMPOUND
WO2022104475A1 (en) * 2020-11-19 2022-05-27 Magicmed Industries Inc. Nitrilated psilocybin derivatives and methods of using
AU2022268420A1 (en) * 2021-05-05 2023-12-21 Kare Chemical Technologies Inc. Catalytic tryptamine processes and precursors
CN113214133B (zh) * 2021-05-08 2023-03-07 河北维达康生物科技有限公司 一种褪黑素的合成方法
CN113960317A (zh) * 2021-08-19 2022-01-21 深圳市辅酶医科技有限公司 一种测量生物样品中nad+浓度的生物传感器及方法
CN113788780B (zh) * 2021-10-15 2023-06-16 河北维达康生物科技有限公司 一种n-乙酰基-5-甲氧基色胺的合成方法
US20250325516A1 (en) 2022-07-08 2025-10-23 Institut Curie Serotonin analogues for use in treating metalloptosis-associated disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437398A1 (fr) * 1978-06-20 1980-04-25 Commissariat Energie Atomique Compose iode utilisable comme traceur en radio-immunologie
DE3613623A1 (de) * 1986-04-23 1987-10-29 Bayer Ag N-dihydroindolylethyl-sulfonamide
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
ATE170839T1 (de) 1994-02-22 1998-09-15 Merrell Pharma Inc Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten
KR100494214B1 (ko) * 1996-03-08 2005-11-25 다케다 야쿠힌 고교 가부시키가이샤 삼환화합물,그의제조방법및용도
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
US6593331B2 (en) 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain
CA2450579A1 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
CN100503566C (zh) * 2001-12-03 2009-06-24 惠氏公司 细胞溶质磷脂酶a2抑制剂
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
JP2007511520A (ja) * 2003-11-13 2007-05-10 ザ ジェネラル ホスピタル コーポレーション 疼痛を治療するための方法
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
WO2006061638A2 (en) 2004-12-10 2006-06-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Heterocycle derivatives as histone deacetylase (hdac) inhibitors
US20090105308A1 (en) * 2005-07-12 2009-04-23 Darren Mansfield Benzoheterocylethylcarboxamide derivatives
AU2006280062A1 (en) 2005-08-10 2007-02-22 Novartis Ag Method of use of deacetylase inhibitors
US7902251B2 (en) * 2005-10-19 2011-03-08 Allergan, Inc. Method for treating pain
RU2425830C2 (ru) 2005-12-01 2011-08-10 Ф. Хоффманн-Ля Рош Аг Новые производные винилогенных кислот
BRPI0619349A2 (pt) 2005-12-05 2011-11-08 Otsuka Pharma Co Ltd agente antitumor, método para tratar ou prevenir tumor, e uso de um composto
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
JP5089185B2 (ja) * 2006-02-02 2012-12-05 大塚製薬株式会社 コラーゲン産生抑制剤。
FR2898358B1 (fr) * 2006-03-08 2008-05-30 Macef Sa Association d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2 par modulation allosterique et leurs utilisations comme produits medicaux
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US20080009485A1 (en) * 2006-05-26 2008-01-10 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
MX2009001327A (es) 2006-08-07 2009-06-05 Ironwood Pharmaceuticals Inc Compuestos de indol.
TW200831498A (en) 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
JP2008115175A (ja) * 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd 複素環化合物
FR2907451B1 (fr) 2006-10-18 2008-12-12 Servier Lab "nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US20080287452A1 (en) * 2007-05-16 2008-11-20 Wyeth Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
TW200914437A (en) * 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2010306750A1 (en) 2012-05-17
EP2488025A1 (en) 2012-08-22
US20120322800A1 (en) 2012-12-20
EP2488025A4 (en) 2013-04-03
JP5758395B2 (ja) 2015-08-05
US20160031812A1 (en) 2016-02-04
JP2013508288A (ja) 2013-03-07
WO2011047156A1 (en) 2011-04-21
CA2777782A1 (en) 2011-04-21
US10059664B2 (en) 2018-08-28
US9169234B2 (en) 2015-10-27
AU2010306750B2 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
CA2777782C (en) Sepiapterin reductase inhibitors for the treatment of pain
AU670477B2 (en) Substituted phenyl sulfonamides as selective Beta3 agonists for the treatment of diabetes and obesity
CN108383836B (zh) 作为mek抑制剂的杂环基化合物
EP1727808B3 (en) Biaryl amino acids and their use in dna binding oligomers
US8685992B2 (en) Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers
CN113939288A (zh) Mas相关g蛋白受体x4的调节剂及相关产物和方法
AU2015360270B9 (en) Piperidine derivatives as HDAC1/2 inhibitors
JP5826972B2 (ja) 酸セラミダーゼインヒビターおよびそれらの医薬としての使用
US10213416B2 (en) Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
BG108487A (bg) Заместени с триамид индоли, бензофурани и бензотиофени като инхибитори на микрозомния триглицерид пренасящ протеин (mtp) и/или секрецията на аполипопротеин б (аро в)
WO2012061926A1 (en) Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
CA2904160A1 (en) Phenyl sulfonamide derivatives and use thereof in the treatment of arthritis
WO2017007695A1 (en) Mu opioid receptor modulators
JP2024528251A (ja) Ｈｄａｃとｎａｄ合成を標的とする多標的阻害剤及びその用途
AU2013215468A1 (en) Benzyl sulfonamide derivatives useful as MOGAT - 2 inhibitors
WO2012120398A1 (en) Aryl substituted carboxamide derivatives as trpm8 modulators
WO2022107745A1 (ja) Ｃｏｖｉｄ－１９の治療剤又は予防剤
JP2007508364A (ja) Ｅｐ４受容体拮抗薬としてのフラン誘導体
EP3325452B1 (en) Substituted hydrophobic benzene sulfonamide thiazole compounds for use in treating cancer
AU715493B2 (en) Selective beta 3 adrenergic agonists
WO2011035009A1 (en) Heterocyclic gtp cyclohydrolase 1 inhibitors for the treatment of pain
KR100820935B1 (ko) 싸이아졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적조성물
KR20240124376A (ko) 벤젠 설폰아미드 티아졸 화합물과 이들의 암 치료 용도
JP7624745B2 (ja) Ｔｒｐｖ４受容体リガンド
US9598381B2 (en) SMYD2 inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191015